Showing 2121-2130 of 4063 results for "".
- Call for Nominations Issued for the 2020 Bonnie Strickland Champion for Children’s Vision Awardhttps://modernod.com/news/call-for-nominations-issued-for-the-2020-bonnie-strickland-champion-for-childrens-vision-award/2477595/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has issued the call for nominations for the sixth annual “Bonnie Strickland Champion for Children’
- Prevent Blindness Issues Call for Nominations for the 2019 Bonnie Strickland Champion for Children’s Vision Awardhttps://modernod.com/news/prevent-blindness-issues-call-for-nominations-for-the-2019-bonnie-strickland-champion-for-childrens-vision-award/2476590/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has issued the call for nominations for the fifth annual Bonnie Strickland Champion for Children’s Vision Award. The award recognizes significant efforts by an individual or group of individuals to improve publ
- MediPrint Ophthalmics Completes Phase 2b Study of Drug-Eluting Contact Lens for Glaucomahttps://modernod.com/news/mediprint-ophthalmics-completion-phase-2b-study-of-drug-eluting-contact-lens-for-glaucoma/2482158/MediPrint Ophthalmics announced it has completed its SIGHT-2 phase 2b study evaluating its lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution. LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens leveraging com
- Penn Medicine Study Finds Missing One Eye Appointment Can Lead to Vision Loss in Elderlyhttps://modernod.com/news/penn-medicine-study-finds-missing-one-eye-appointment-can-lead-to-vision-loss-in-elderly/2477319/A Penn Medicine study discovered that missing one ophthalmology appointment within a 2-year period could cause dec
- Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512 for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-positive-topline-results-from-phase-3-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye/2482063/Alcon announced positive topline results from the two pivotal phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 93
- LumiThera Receives NIH Grant to Support Dry AMD Trialhttps://modernod.com/news/lumithera-receives-nih-grant-to-support-dry-amd-trial/2481855/LumiThera announced it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) of up to $2.3 million in funding over 2 years. The NIH/NEI grant supports an open-label human clinical trial in intermediate dry
- FDA Clearance Expands the Label of Eyenuk's EyeArt AI System for the Detection of DRhttps://modernod.com/news/fda-clearance-expands-the-label-of-eyenuks-eyeart-ai-system-for-the-detection-of-dr/2481685/Eyenuk has received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras. The regulatory clearance of t
- Essilor to Present New Results for its Stellest Lens for Children With Myopiahttps://modernod.com/news/essilor-to-present-new-results-for-its-stellest-lens-for-children-with-myopia/2479062/Essilor will unveil pivotal 2-year clinical trial results of its Stellest lens for myopia. The 2-year results demonstrate that Essilor Stellest lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day,1 according to
- Oyster Point Submits NDA to FDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-submits-nda-to-fda-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478677/Oyster Point Pharma announced it has submitted a 505(b)(2) new drug application (NDA) to the FDA for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease. The NDA submission is supported by safety and efficacy results from the phase 3 ONSET-2, phase 2b ONSET-
- Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-late-breaking-presentation-of-targeted-c3-therapy-pegcetacoplan-in-patients-with-geographic-atrophy-ga/2478309/Apellis Pharmaceuticals announced that a post hoc analysis of the phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETIN